Scientific article
Open access

Gestion péri-interventionnelle des nouveaux agents antiplaquettaires

Published inRevue médicale suisse, vol. 9, no. 372, p. 326-330
Publication date2013

The management of antiplatelet drugs in the perioperative setting is based on an individual evaluation of the thrombotic and bleeding risks. When the bleeding risk is deemed low, continuation of the dual antiplatelet therapy is usually recommended, especially in high thrombotic risk settings. When the bleeding risk is deemed moderate, at least one antiplatelet agent should be continued, usually aspirin, and clopidogrel and ticagrelor should be discontinued 5 days and prasugrel 7 days before surgery. In some rare instances of high bleeding risk, discontinuation of aspirin 3 days before surgery is usually acceptable. In high thrombotic settings, bridging with an intravenous antiplatelet drug with a short half-life may be considered.

  • Hemorrhage/prevention & control
  • Humans
  • Perioperative Care
  • Platelet Aggregation Inhibitors/therapeutic use
  • Risk Assessment
  • Thrombosis/prevention & control
Citation (ISO format)
SCHNYDER-JORIS, Coralie et al. Gestion péri-interventionnelle des nouveaux agents antiplaquettaires. In: Revue médicale suisse, 2013, vol. 9, n° 372, p. 326–330.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation09/01/2013 10:03:00 PM
First validation09/01/2013 10:03:00 PM
Update time03/14/2023 8:24:15 PM
Status update03/14/2023 8:24:14 PM
Last indexation01/16/2024 2:07:33 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack